Opendata, web and dolomites

FERTISSIMO

Oxidative Stress as a biomarker for Embryo Selection in IVF Process

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FERTISSIMO project word cloud

Explore the words cloud of the FERTISSIMO project. It provides you a very rough idea of what is the project "FERTISSIMO" about.

fertissimo    business    sound    quantitative    multiple    published    strategy    2009    preparing    rates    profile    probability    grant    fertility    proprietary    pregnancy    biomarker    patented    series    merck    economical    launch    innovation    clinical    won    practitioner    magazines    incidence    roadmap    eureka    supply    oxidative    physicians    2014    competition    embryo    proof    solid    reproductive    carmel    prestigious    levels    validation    point    reducing    ivf    gfi    diagnostics    solution    body    meet    serono    stable    media    invasive    care    sme    ip    abstract    embryos    culture    enabled    chf    huge    approved    deploying    linked    stratification    platform    thermochemiluminescence    thrilled    plan    model    generation    patients    trade    examination    june    fluids    tcl    successfully    implantation    births    stress    units    risk    ultimate    commercialization    analyzer    completion    incubated    route    chain    biomarkers    market   

Project "FERTISSIMO" data sheet

The following table provides information about the project.

Coordinator
CARMEL DIAGNOSTICS LTD 

Organization address
address: 9 BARLEV HAIM STREET
city: QIRYAT TIVON
postcode: 3608267
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.carmel-diagnostics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARMEL DIAGNOSTICS LTD IL (QIRYAT TIVON) coordinator 50˙000.00

Map

 Project objective

Abstract: Carmel Diagnostics, established in 2009, is an SME that has developed clinical applications of its novel, proprietary, patented Thermochemiluminescence technology platform – TCL Analyzer™. Carmel has successfully completed “proof of concept” for its main applications: Embryo Selection in IVF process and Risk Stratification for CHF patients. The results were published in leading magazines. The technology enables assessment of Oxidative Stress in body fluids using it as a biomarker for clinical problems linked to levels of oxidative stress. TCL Analyzer is a stable, robust Point of Care system, now in its third generation. There is a huge need, clinical and economical, for novel biomarkers that will enable the physicians with effective embryo selection. With the goal of identifying embryos of high implantation probability, Carmel’s non-invasive solution will meet this need by providing a quantitative assessment of an embryo’s reproductive potential based on a biomarker - the oxidative profile of the culture media in which the embryo is incubated. This will allow the practitioner to improve pregnancy rates while reducing the incidence of multiple births. The Phase-1 project will be focused on preparing sound business plan, based on solid business model and commercialization strategy and to plan the activities for deploying the solution. This will include market and competition analysis, IP analysis, supply chain examination, risk assessment, and preparing roadmap for the clinical validation, product completion and the best route to bring the system to the market and launch it successfully. In June, 2014 Carmel won a prestigious grant of GFI - Grant for Fertility Innovation (by Merck Serono) that enabled it to build a series of improved, stable TCL Analyzer units to be used in the clinical studies. Eureka approved the project as well. Carmel’s experienced management is thrilled to build FERTISSIMO, the ultimate Embryo selection system based on TCL Analyzer.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FERTISSIMO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FERTISSIMO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More